Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's...
China International College Students' Innovation Competition 2025 Finals Conclude in Zhengzhou
ZHENGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- In a report published by Xinhua News Agency, the finals of the China International College Students' Innovation Competition 2025 were held in Zhengzhou from October 13 to 15. Co-organized by the...
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate...
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key...
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a...
HARMONi-6 dаta: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged...
From Test Drive to Co-Creation -- The 2025 Chery International User Summit Builds a New Mobility Ecosystem
WUHU, China, Oct. 19, 2025 /PRNewswire/ -- From October 17 to 21, under the theme "Co-Create • Co-Define," the 2025 Chery International User Summit gathered 1,200 guests from over 100 countries and regions in Wuhu. The event offered an immersive...
HKUST Holds Congregation 2025 Conferring Honorary Doctorates on Five Distinguished Leaders
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- The Hong Kong University of Science and Technology (HKUST) today held its Congregation 2025, conferring Honorary Doctorates upon five prominent and distinguished leaders. The awards were presented by HKUST...
The Grand Opening of 2025 Chery Global Innovation Conference: Gathering Global Wisdom, Driving the Future with Innovation
WUHU, China, Oct. 18, 2025 /PRNewswire/ -- On October 18, 2025, the 2025 Chery Global Innovation Conference officially kicked off under the theme "Innovation • Leading the World with Intelligence." The conference systematically presented Chery...